Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

ecember 31, December 31,

(in thousands of U.S.$) 2007 2006

-------------------------------------------------------------------------

ASSETS

Cash and short-term investments 91,326 108,617

Accounts receivable 22,678 25,231

Inventories 33,647 33,619

Deferred income taxes 5,964 5,372

Other current assets 7,070 6,303

Assets from discontinued operations - 2,365

-------------------------------------------------------------------------

Total current assets 160,685 181,507

-------------------------------------------------------------------------

Long-term investments 24,456 53,840

Property and equipment, net 59,187 59,783

Intangible assets, net 225,889 244,954

Goodwill 660,591 630,770

Deferred income taxes - 4,804

Deferred financing costs 13,600 14,845

Other assets 6,780 255

Assets from discontinued operations - 15,116

-------------------------------------------------------------------------

Total assets 1,151,188 1,205,874

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities 67,182 67,950

Liabilit
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email: